AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Core Viewpoint - AIM ImmunoTech is set to present its lead program, Ampligen, for the treatment of pancreatic cancer during a virtual investor event on February 19, 2026, highlighting its clinical and regulatory strategy [1][2]. Group 1: Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing Ampligen (rintatolimod) for late-stage pancreatic cancer, addressing a significant global health issue [4]. - Ampligen is characterized as a dsRNA and highly selective TLR3 agonist immuno-modulator, demonstrating broad-spectrum activity in clinical trials [4]. Group 2: Event Details - Thomas K. Equels, the CEO of AIM, will participate in a Virtual Investor Closing Bell Event on February 19, 2026, at 4:00 PM ET [1]. - The event will emphasize the ongoing DURIPANC clinical trial, which involves a collaboration with AstraZeneca, combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), for treating metastatic pancreatic cancer [2]. - A live video webcast of the presentation will be available on the company's website, with a replay accessible for 90 days after the event [3].